You are subscribed to Oncology Drugs. This information has recently been updated, and is now available. Food and Drug Administration granted accelerated approval to axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. More Information. March 5, 2021 |
No comments:
Post a Comment